Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluzone HD Quadrivalent Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

NCT02915302
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
1,950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Harrisburg, Arkansas • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

NCT05553301
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5407, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Rolling Hills Estates, California • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 8, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older

NCT04622592
View directory record Official record
Conditions
Influenza
Interventions
Instramuscular vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
14
States / cities
Huntsville, Alabama • Chandler, Arizona • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05827978
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8,411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
103
States / cities
Anniston, Alabama • Athens, Alabama • Cullman, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immune and Hormone Response to Influenza Vaccine

NCT01978262
View directory record Official record
Conditions
Healthy
Interventions
Seasonal Inactivated Influenza Vaccine
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Sep 8, 2026, 10:08 PM EDT
Not listed No phase listed Observational

National Vaccine Adverse Event Reporting Survey and Etiology

NCT05095844
View directory record Official record
Conditions
COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use, Corona Virus Infection, Blood Clot, Thrombocytopenia, Neuritis, Vasculitis, Influenza, Guillain-Barré, GWAS, Genetic Sequencing
Interventions
vaccinated
Biological
Lead sponsor
Neuroganics LLC
Industry
Eligibility
5 Years to 99 Years
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Northglenn, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 8, 2026, 10:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

NCT05426174
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
mRNA NA vaccine, High Dose Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous RZV and aIIV4 Vaccination

NCT05007041
View directory record Official record
Conditions
Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions
FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®
Biological
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 8, 2026, 10:08 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults

NCT01946438
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),, Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 8, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

NCT03308825
View directory record Official record
Conditions
Influenza, Flu
Interventions
Fluzone Quadrivalent vaccine, Fluzone High-Dose vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Council Bluffs, Iowa • Bardstown, Kentucky • Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

NCT04120194
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu, Fluzone Quadrivalent
Biological
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
2,654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
19
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

NCT06744205
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years and older
Enrollment
1,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
21
States / cities
Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 8, 2026, 10:08 PM EDT
Recruiting Phase 1 Interventional

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

NCT04697576
View directory record Official record
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab
Biological · Procedure
Lead sponsor
Carlo Contreras
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 8, 2026, 10:08 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

NCT02500680
View directory record Official record
Conditions
Influenza, Human
Interventions
MER4101, Inactivated Influenza Vaccine
Biological
Lead sponsor
Nova Immunotherapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 8, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 49 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 8, 2026, 10:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

NCT02554409
View directory record Official record
Conditions
Pregnancy, Influenza
Interventions
Quadrivalent Intradermal Influenza Vaccine (QIV)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Albany, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 8, 2026, 10:08 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Response to Inactivated Influenza Vaccine in Lymph Tissue and Blood

NCT03898973
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent inactivated influenza vaccine (IIV)
Biological
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 8, 2026, 10:08 PM EDT